Plasmodium falciparum dhps and dhfr markers of resistance to sulfadoxine–pyrimethamine five years (2016–2020) after the implementation of seasonal malaria chemoprevention in Cameroon [version 1; peer review: 2 approved, 1 approved with reservations]

Background Antimalarial drug resistance is a major challenge in the fight against malaria. Cameroon implemented seasonal malaria chemoprevention (SMC) with sulfadoxine–pyrimethamine and amodiaquine (SPAQ) to over 1.5 million children aged 3–59 months from 2016, raising concerns whether drug pressure...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Wellcome Open Research
المؤلفون الرئيسيون:	Palmer M. Netongo, Akindeh M. Nji, Peter Thelma N. Niba, Innocent M. Ali, Randolph Ngwafor, Calvino F. Tah, Germaine Ekoyol, William D. Nana, Jude D. Bigoga, Dorothy F. Ashu, Wilfried F. Mbacham, Christopher B. Tume, Pacome V. K. Tchuenkam, Jean Paul K. Chedjou, Lesley N. Ngum
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Wellcome 2024-06-01
الموضوعات:	sulfadoxine–pyrimethamine drug resistance plasmodium falciparum chemoprevention Pfdhps Cameroon eng
الوصول للمادة أونلاين:	https://wellcomeopenresearch.org/articles/9-323/v1